Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study-Reference-Cited by-同舟云学术

Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study

Published:2024-06 Issue:6 Volume:30 Page:630.e1-630.e8
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Caillot Leo^ORCID,Sleiman Emmanuel,Lafon Ingrid,Chretien Marie-Lorraine,Gueneau Pauline,Payssot Alexandre,Pedri Romain,Lakomy Daniela,Bailly François,Guy Julien,Quenot Jean-Pierre,Avet-Loiseau Herve,Caillot Denis^ORCID

Publisher

Elsevier BV

Reference11 articles.

1. Idecabtagene vicleucel in relapsed and refractory multiple myeloma;Munshi;N Engl J Med,2021

2. Celgene Corporation, a Bristol-Myers Squibb Company. ABECMA (Idecabtagene-vicleucel) [package insert]. March 2021. Available at: https://packageinserts.bms.com/pi/pi_abecma.pdf. Accessed August 1, 2023.

3. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma;Kumar;Lancet Oncol,2016

4. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma;Corre;Blood,2021

5. Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma – a meta-analysis of 2,596 trial patients;Weinhold;Haematologica,2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy;Nature Medicine;2024-07-08

2. Idecabtagene-vicleucel;Reactions Weekly;2024-06-29